Reviews/Vitamin B12/Metformin lowers vitamin B12
Deficiency And Status · VITB12-STATUS-02 · v2
Several controlled trials in this corpus measured what happens to vitamin B12 in the blood of people taking metformin, and they point the same way. A 4.3-year placebo-controlled trial found metformin cut B12 by an average of 19% [1], and a very long extension study linked each additional year of metformin to a higher chance of low B12 [2]. Further trials in different groups of people found B12 was lower after metformin at 6 months [11] and over 3 years [12]. One study found no overall difference between metformin and non-metformin groups, but even there B12 fell as the dose rose [9]. The main open question is whether a fall in blood levels always means the body is truly short of the vitamin [6][7]; that concerns the vitamin's downstream effects, not whether blood levels drop.
Direct, replicated controlled-trial evidence shows metformin lowering circulating vitamin B12. The 4.3-year HOME trial recorded a mean decrease of -19% versus placebo [1], and the DPP/DPPOS extension associated years of metformin use with B12 deficiency (odds ratio 1.13 per year) [2]. Independent randomized trials in non-diabetic breast-cancer patients (320 vs 380 pmol/L at 6 months, p=0.0001) [11] and in women over 3 years (a significant overall reduction) [12] reproduce the effect in different populations. A before-after study [19] and a rat experiment showing a 22% plasma fall [7] add dose-duration and mechanistic support, while a post-hoc analysis confirms metformin reduces serum B12 and progressively raises methylmalonic acid [6]. The contested point: The evidence divides on interpretation rather than direction: the Japanese cross-sectional study [9] found no significant overall B12 difference between metformin and control groups, with the effect appearing only as a dose-negative correlation and among elderly patients. Separately, [7] shows metformin redistributes B12 (liver 36% higher, kidney 34% lower) rather than reducing absorption, and [6] calls tissue deficiency controversial, raising whether the serum fall fully reflects true depletion.
All 22 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Vitamin B12, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
A null primary result exists: [9] reports B12 did not differ significantly between metformin and control groups overall, with the effect appearing only in dose-correlation and elderly subsets.
Serum vs tissue indirection: [7] shows metformin redistributes B12 (liver +36%, kidney -34%) and [6] calls tissue deficiency 'controversial', so a fall in serum levels may overstate true B12 depletion — though the claim concerns levels, which are unambiguously lowered.
Where it remains uncertain. One cross-sectional study found no overall group difference, only a dose-dependent decline [9], and animal data suggest the serum fall reflects tissue redistribution rather than depletion [7].
Aleatory
The cross-sectional study [9] found no significant overall B12 difference between groups, with the signal surfacing only in dose correlation and the elderly subset.
Epistemic
Several included trials are short-term or in special populations ([11] 6 months, [8] pregnancy, [7] rats, [12] mixed metabolic syndrome), so genuinely long-term evidence rests mainly on [1] and [2].
Inferential
[7] shows redistribution (liver 36% higher, kidney 34% lower) and [6] calls tissue deficiency controversial, so a serum fall may not equal true whole-body depletion.
The load-bearing papers from a corpus of 22, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Long-term (4.3 y) placebo-controlled RCT quantifying the lowering effect directly on-claim.
“Compared with placebo, metformin treatment was associated with a mean decrease in vitamin B-12 concentration of -19% (95% confidence interval -24% to -14%; P<0.001)”
Panel auditInternal validity: high · scope of inference: Insulin-treated type 2 diabetes patients over 4.3 years of metformin.Key limitations: all patients on background insulin · single-country outpatient setting
Largest long-term dataset showing a duration-dependent lowering/deficiency effect.
“Years of metformin use were associated with increased risk of B12 deficiency (odds ratio, B12 deficiency/year metformin use, 1.13; 95% confidence interval, 1.06–1.20).”
Panel auditInternal validity: high · scope of inference: Prediabetic/overweight adults in the DPP/DPPOS over up to 13 years.Key limitations: open-label metformin after 3.2 years · analysis restricted to stored-sample subset · 13-year difference non-significant
Post-hoc confirmation of progressive serum B12 reduction over long-term treatment.
“Metformin not only reduces serum levels of B12, but also progressively increases serum MMA.”
Panel auditInternal validity: high · scope of inference: Insulin-treated type 2 diabetes patients over 52 months.Key limitations: post hoc analysis · no numeric B12 effect size in abstract · same cohort as [1]
Additional duration/dose association consistent with the lowering effect.
“Low serum vitamin B12 level is associated with longer duration and higher dose of metformin use.”
Panel auditInternal validity: low · scope of inference: Type 2 diabetes patients over 6 months of metformin.Key limitations: no control arm · sample size not reported · before-after confounding
4 of 22 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Replicated, direct, long-term controlled-trial evidence consistently shows metformin lowering serum vitamin B12, with no contradictory result on the direction of effect.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Serum decline versus functional tissue status. The verdict concerns levels, but the corpus itself disputes whether the serum fall marks true depletion [6][7], which shapes how much the lowered level matters. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A long-term RCT pairing serum B12 with functional markers (methylmalonic acid, holotranscobalamin) and clinical outcomes across the treatment period.
Open question: Does the metformin-associated fall in serum B12 correspond to functionally deficient tissue status over the long term? Why it is still open: [6] reports rising methylmalonic acid while [7] attributes the serum fall to redistribution into the liver, leaving the functional meaning unsettled.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19